​

Rapport Therapeutics Ownership | Who Owns Rapport Therapeutics?

OverviewForecastRevenueFinancialsChart

Rapport Therapeutics Ownership Summary

Rapport Therapeutics is owned by 108.97% institutional investors, 4.47% insiders. Fmr is the largest institutional shareholder, holding 15.19% of RAPP shares. American Funds SMALLCAP World A is the top mutual fund, with 7.07% of its assets in Rapport Therapeutics shares.

RAPP Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockRapport Therapeutics108.97%4.47%-13.44%
SectorHealthcare Stocks 50.49%12.37%37.14%
IndustryBiotech Stocks 48.95%12.07%38.98%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr7.17M15.19%$298.89M
Trv gp v6.28M13.30%$261.71M
Arch venture management3.73M7.89%$155.38M
Capital investors2.92M6.19%$121.76M
Goldman sachs group2.91M6.16%$121.28M
Blackrock funding, inc. /de2.70M5.72%$112.50M
Cormorant asset management, lp2.66M5.63%$110.74M
Sofinnova investments1.90M4.03%$79.36M
Johnson & johnson1.78M3.78%$74.36M
Polar capital1.61M3.41%$67.03M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Trv gp v6.28M52.53%$261.71M
Trv gp vi969.22K17.39%$40.39M
Arch venture management3.73M14.12%$155.38M
Johnson & johnson1.78M9.31%$74.36M
Cormorant asset management, lp2.66M5.67%$110.74M
Sofinnova investments1.90M4.10%$79.36M
Sio capital management307.66K2.12%$12.82M
Artia global partners lp138.51K1.07%$5.77M
Sphera funds management157.53K0.99%$4.68M
Vestal point capital, lp730.00K0.71%$30.42M

Top Buyers

HolderShares% AssetsChange
Sixth street partners management company246.81K0.00%246.81K
Algert global223.82K0.11%223.82K
Blackrock funding, inc. /de2.70M0.00%193.83K
Vanguard group1.82M0.00%191.22K
Candriam s.c.a.347.65K0.07%161.72K

Top Sellers

HolderShares% AssetsChange
Trv gp v6.28M52.53%-854.71K
Vestal point capital, lp730.00K0.71%-706.23K
Cormorant asset management, lp2.66M5.67%-300.00K
Ubs asset management americas644.08K0.00%-274.78K
Franklin resources---250.59K

New Positions

HolderShares% AssetsChangeValue
Sixth street partners management company246.81K0.00%246.81K$10.28M
Algert global223.82K0.11%223.82K$9.33M
Sphera funds management157.53K0.99%157.53K$4.68M
Woodline partners lp97.54K0.01%97.54K$4.06M
Fort baker capital management lp81.64K0.38%81.64K$2.42M

Sold Out

HolderChange
Farther finance advisors-1.00
Mai capital management-6.00
Clearstead advisors-33.00
Rise advisors-50.00
Parallel advisors-50.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202616410.81%51,474,063-1.92%1080.87%887.32%4429.41%
Mar 31, 202675-48.28%16,611,270-67.48%350.20%41-54.95%18-41.94%
Dec 31, 202593-29.55%28,333,513-42.50%73.86%62-30.34%16-11.11%
Sep 30, 202512969.74%49,256,68336.76%1313.46%87102.33%1812.50%
Jun 30, 2025805.26%38,487,48429.20%1015.22%45-15.09%18100.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
American Funds SMALLCAP World A3.38M7.07%-254.97K
Fidelity Growth Compy Commingled Pl S3.20M6.69%-
Fidelity Growth Company Fund2.25M4.70%-2.78K
Polar Capital Biotech S Inc1.52M3.19%-
Vanguard Total Stock Mkt Idx Inv986.73K2.06%13.40K
Vanguard Morn Total Stk Mkt Idx Investor986.73K2.06%13.40K
Vanguard MStar Total Stk Mkt Idx Invest986.73K2.06%-
iShares Russell 2000 ETF781.04K1.63%-13.92K
Fidelity Growth Company K6689.89K1.44%2.78K
Fidelity Series Growth Company592.11K1.24%-

Recent Insider Transactions

DateNameRoleActivityValue
Aug 19, 2026Yeleswaram Krishnaswamy Chief Development OfficerSell$20.16K
Aug 11, 2026Ceesay Abraham Chief Executive OfficerSell$936.85K
Aug 10, 2026Ceesay Abraham Chief Executive OfficerSell$391.28K
Aug 10, 2026Ceesay Abraham Chief Executive OfficerSell$651.49K
Aug 11, 2026Ceesay Abraham Chief Executive OfficerSell$171.84K

Insider Transactions Trends

DateBuySell
2026 Q3-10
2026 Q2-16
2026 Q1-15
2025 Q4-23
2025 Q3410

RAPP Ownership FAQ

Who Owns Rapport Therapeutics?

Rapport Therapeutics shareholders are primarily institutional investors at 108.97%, followed by 4.47% insiders and -13.44% retail investors. The average institutional ownership in Rapport Therapeutics's industry, Biotech Stocks , is 48.95%, which Rapport Therapeutics exceeds.

Who owns the most shares of Rapport Therapeutics?

Rapport Therapeutics’s largest shareholders are Fmr (7.17M shares, 15.19%), Trv gp v (6.28M shares, 13.30%), and Arch venture management (3.73M shares, 7.89%). Together, they hold 36.37% of Rapport Therapeutics’s total shares outstanding.

Does Blackrock own Rapport Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Rapport Therapeutics.

Who is Rapport Therapeutics’s biggest shareholder by percentage of total assets invested?

Trv gp v is Rapport Therapeutics’s biggest shareholder by percentage of total assets invested, with 52.53% of its assets in 6.28M Rapport Therapeutics shares, valued at 261.71M$.

Who is the top mutual fund holder of Rapport Therapeutics shares?

American Funds SMALLCAP World A is the top mutual fund holder of Rapport Therapeutics shares, with 7.07% of its total shares outstanding invested in 3.38M Rapport Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools